Reliable Diagnosis from Blood Samples

Data published in BMC Cancer and PLoS ONE show that Febits tailored biochips enable the identification of Mi RNA biomarker signatures for diagnosing lung cancer and multiple sclerosis from blood samples. The invasive and often painful procedure of collecting patient tissue samples may become obsolete in the coming years, the company announced. A research group led by Prof. Eckart Meese at the University of Saarland (Germany) investigated the performance of the analysis method developed by Febit Biomed in patients with non-small cell lung cancer (NSCLC) and in patients suffering from multiple sclerosis. Using the companys Geniom RT Analyzer, biomarker sets of 24 (lung cancer) and 48 (multiple sclerosis) Mi RNAs have been identified. They provide accurate discrimination of patients with NSCLC or multiple sclerosis from healthy individuals with 95% accuracy.